Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.

Sobarzo A, Stonier SW, Radinsky O, Gelkop S, Kuehne AI, Edri A, Herbert AS, Fedida-Metula S, Lutwama JJ, Yavelsky V, Davis C, Porgador A, Dye JM, Lobel L.

EBioMedicine. 2019 Aug;46:215-226. doi: 10.1016/j.ebiom.2019.07.021. Epub 2019 Jul 17.

2.

Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model.

Quartey QQ, Miller RJ, Pinsker BL, Okoh UJ, Shipman WD, George BA, Nwizu CC, Barnes LA, Kerns ML, Caffrey JA, Aliu O, Brown ID, Succaria F, Maynard JP, Herbert AS, Kang S, Miller LS, Okoye GA, Byrd AS.

Clin Exp Dermatol. 2019 Jul 19. doi: 10.1111/ced.14054. [Epub ahead of print]

PMID:
31322280
3.

Structural basis of broad ebolavirus neutralization by a human survivor antibody.

West BR, Wec AZ, Moyer CL, Fusco ML, Ilinykh PA, Huang K, Wirchnianski AS, James RM, Herbert AS, Hui S, Goodwin E, Howell KA, Kailasan S, Aman MJ, Walker LM, Dye JM, Bukreyev A, Chandran K, Saphire EO.

Nat Struct Mol Biol. 2019 Mar;26(3):204-212. doi: 10.1038/s41594-019-0191-4. Epub 2019 Mar 4.

4.

A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.

Bornholdt ZA, Herbert AS, Mire CE, He S, Cross RW, Wec AZ, Abelson DM, Geisbert JB, James RM, Rahim MN, Zhu W, Borisevich V, Banadyga L, Gunn BM, Agans KN, Wirchnianski AS, Goodwin E, Tierney K, Shestowsky WS, Bohorov O, Bohorova N, Velasco J, Ailor E, Kim D, Pauly MH, Whaley KJ, Alter G, Walker LM, Chandran K, Zeitlin L, Qiu X, Geisbert TW, Dye JM.

Cell Host Microbe. 2019 Jan 9;25(1):49-58.e5. doi: 10.1016/j.chom.2018.12.005.

PMID:
30629918
5.

Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.

Wec AZ, Bornholdt ZA, He S, Herbert AS, Goodwin E, Wirchnianski AS, Gunn BM, Zhang Z, Zhu W, Liu G, Abelson DM, Moyer CL, Jangra RK, James RM, Bakken RR, Bohorova N, Bohorov O, Kim DH, Pauly MH, Velasco J, Bortz RH 3rd, Whaley KJ, Goldstein T, Anthony SJ, Alter G, Walker LM, Dye JM, Zeitlin L, Qiu X, Chandran K.

Cell Host Microbe. 2019 Jan 9;25(1):39-48.e5. doi: 10.1016/j.chom.2018.12.004.

PMID:
30629917
6.

Protocadherin-1 is essential for cell entry by New World hantaviruses.

Jangra RK, Herbert AS, Li R, Jae LT, Kleinfelter LM, Slough MM, Barker SL, Guardado-Calvo P, Román-Sosa G, Dieterle ME, Kuehne AI, Muena NA, Wirchnianski AS, Nyakatura EK, Fels JM, Ng M, Mittler E, Pan J, Bharrhan S, Wec AZ, Lai JR, Sidhu SS, Tischler ND, Rey FA, Moffat J, Brummelkamp TR, Wang Z, Dye JM, Chandran K.

Nature. 2018 Nov;563(7732):559-563. doi: 10.1038/s41586-018-0702-1. Epub 2018 Nov 21.

7.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

8.

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.

Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G.

Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.

9.

Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.

Froude JW, Herbert AS, Pelat T, Miethe S, Zak SE, Brannan JM, Bakken RR, Steiner AR, Yin G, Hallam TJ, Sato AK, Hust M, Thullier P, Dye JM.

Viruses. 2018 May 26;10(6). pii: E286. doi: 10.3390/v10060286.

10.

NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry.

Raaben M, Jae LT, Herbert AS, Kuehne AI, Stubbs SH, Chou YY, Blomen VA, Kirchhausen T, Dye JM, Brummelkamp TR, Whelan SP.

Cell Host Microbe. 2017 Nov 8;22(5):688-696.e5. doi: 10.1016/j.chom.2017.10.002.

11.

Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.

Stonier SW, Herbert AS, Kuehne AI, Sobarzo A, Habibulin P, Dahan CVA, James RM, Egesa M, Cose S, Lutwama JJ, Lobel L, Dye JM.

J Exp Med. 2017 Sep 4;214(9):2563-2572. doi: 10.1084/jem.20170161. Epub 2017 Jul 19.

12.

Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W.

J Virol. 2017 Aug 10;91(17). pii: e00479-17. doi: 10.1128/JVI.00479-17. Print 2017 Sep 1.

13.

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega MA, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA.

Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.

14.

Radiation Safety in Children With Congenital and Acquired Heart Disease: A Scientific Position Statement on Multimodality Dose Optimization From the Image Gently Alliance.

Hill KD, Frush DP, Han BK, Abbott BG, Armstrong AK, DeKemp RA, Glatz AC, Greenberg SB, Herbert AS, Justino H, Mah D, Mahesh M, Rigsby CK, Slesnick TC, Strauss KJ, Trattner S, Viswanathan MN, Einstein AJ; Image Gently Alliance.

JACC Cardiovasc Imaging. 2017 Jul;10(7):797-818. doi: 10.1016/j.jcmg.2017.04.003. Epub 2017 May 18. Review.

15.

Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Kash JC, Walters KA, Kindrachuk J, Baxter D, Scherler K, Janosko KB, Adams RD, Herbert AS, James RM, Stonier SW, Memoli MJ, Dye JM, Davey RT Jr, Chertow DS, Taubenberger JK.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaai9321. doi: 10.1126/scitranslmed.aai9321.

16.

Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.

Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, Herbert AS, Qiu X, Doranz BJ, Holtsberg FW, Ward AB, Dye JM, Aman MJ.

Cell Rep. 2017 Apr 11;19(2):413-424. doi: 10.1016/j.celrep.2017.03.049.

17.

A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.

Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K.

Science. 2016 Oct 21;354(6310):350-354. Epub 2016 Sep 8.

18.

Cysteine Cathepsin Inhibitors as Anti-Ebola Agents.

van der Linden WA, Schulze CJ, Herbert AS, Krause TB, Wirchnianski AA, Dye JM, Chandran K, Bogyo M.

ACS Infect Dis. 2016 Mar 11;2(3):173-179. Epub 2016 Jan 20.

19.

A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles.

Ndungo E, Herbert AS, Raaben M, Obernosterer G, Biswas R, Miller EH, Wirchnianski AS, Carette JE, Brummelkamp TR, Whelan SP, Dye JM, Chandran K.

mSphere. 2016 Mar 30;1(2). pii: e00007-16. doi: 10.1128/mSphere.00007-16. eCollection 2016 Mar-Apr.

20.

Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors.

Sobarzo A, Stonier SW, Herbert AS, Ochayon DE, Kuehne AI, Eskira Y, Fedida-Metula S, Tali N, Lewis EC, Egesa M, Cose S, Lutwama JJ, Yavelsky V, Dye JM, Lobel L.

Viruses. 2016 May 11;8(5). pii: E133. doi: 10.3390/v8050133.

21.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.

22.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

23.

Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats.

Ng M, Ndungo E, Kaczmarek ME, Herbert AS, Binger T, Kuehne AI, Jangra RK, Hawkins JA, Gifford RJ, Biswas R, Demogines A, James RM, Yu M, Brummelkamp TR, Drosten C, Wang LF, Kuhn JH, Müller MA, Dye JM, Sawyer SL, Chandran K.

Elife. 2015 Dec 23;4. pii: e11785. doi: 10.7554/eLife.11785.

24.

Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.

Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ.

J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1.

25.

Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, Aman MJ.

J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.

26.

Novel Small Molecule Entry Inhibitors of Ebola Virus.

Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, Dye JM, Moir DT, Chandran K, Patterson JL, Rong L, Bowlin TL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S425-34. doi: 10.1093/infdis/jiv223. Epub 2015 Jul 22.

27.

Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion.

Kleinfelter LM, Jangra RK, Jae LT, Herbert AS, Mittler E, Stiles KM, Wirchnianski AS, Kielian M, Brummelkamp TR, Dye JM, Chandran K.

MBio. 2015 Jun 30;6(4):e00801. doi: 10.1128/mBio.00801-15.

28.

Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo.

Herbert AS, Davidson C, Kuehne AI, Bakken R, Braigen SZ, Gunn KE, Whelan SP, Brummelkamp TR, Twenhafel NA, Chandran K, Walkley SU, Dye JM.

MBio. 2015 May 26;6(3):e00565-15. doi: 10.1128/mBio.00565-15.

29.

Immune memory to Sudan virus: comparison between two separate disease outbreaks.

Sobarzo A, Eskira Y, Herbert AS, Kuehne AI, Stonier SW, Ochayon DE, Fedida-Metula S, Balinandi S, Kislev Y, Tali N, Lewis EC, Lutwama JJ, Dye JM, Yavelsky V, Lobel L.

Viruses. 2015 Jan 6;7(1):37-51. doi: 10.3390/v7010037.

30.

Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets.

Clinton TR, Weinstock MT, Jacobsen MT, Szabo-Fresnais N, Pandya MJ, Whitby FG, Herbert AS, Prugar LI, McKinnon R, Hill CP, Welch BD, Dye JM, Eckert DM, Kay MS.

Protein Sci. 2015 Apr;24(4):446-63. doi: 10.1002/pro.2578. Epub 2014 Oct 31.

31.

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Viruses. 2014 Sep 26;6(9):3663-82. doi: 10.3390/v6093663.

32.

Virus entry. Lassa virus entry requires a trigger-induced receptor switch.

Jae LT, Raaben M, Herbert AS, Kuehne AI, Wirchnianski AS, Soh TK, Stubbs SH, Janssen H, Damme M, Saftig P, Whelan SP, Dye JM, Brummelkamp TR.

Science. 2014 Jun 27;344(6191):1506-10. doi: 10.1126/science.1252480.

33.

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.

34.

Niemann-Pick C1 (NPC1)/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor.

Krishnan A, Miller EH, Herbert AS, Ng M, Ndungo E, Whelan SP, Dye JM, Chandran K.

Viruses. 2012 Oct 25;4(11):2471-84. doi: 10.3390/v4112471.

35.

Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.

Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5034-9. doi: 10.1073/pnas.1200409109. Epub 2012 Mar 12.

36.

Ebola virus entry requires the host-programmed recognition of an intracellular receptor.

Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K.

EMBO J. 2012 Apr 18;31(8):1947-60. doi: 10.1038/emboj.2012.53. Epub 2012 Mar 6.

37.

Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.

Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR.

Nature. 2011 Aug 24;477(7364):340-3. doi: 10.1038/nature10348.

38.
39.

The Significance of the Jaw-neck Syndrome in the Rheumatic Group of Diseases.

Herbert AS.

Proc R Soc Med. 1921;14(Ther Pharmacol Sect):1-5. No abstract available.

Supplemental Content

Loading ...
Support Center